Biosortia is a therapeutics, agrochemical and cosmetics company developing products from microbial small molecules through microbiome mining. Biosortia establishes libraries of natural molecule activity and derivatives from microorganisms extracted from the natural world. Biosortia is in the JLABS incubator and received a $1 million annual recurring revenue (ARR) contract with the Department of Homeland Security.
As part of their cancer drug discovery research Biosortia tests compounds isolated from microorganisms on cancer cell lines. Biosortia sampled from cyanobacterial blooms in Buckeye Lake and Grand Lake St. Marys in Ohio and disovered a new series of cardiotoxic steroids. The group also discovered new cytotoxic compounds from a Microcystis aeruginosa bloom.
Cyanobufalins: Cardioactive Toxins from Cyanobacterial Blooms
Microcystins Containing Doubly Homologated Tyrosine Residues from a Microcystis aeruginosa Bloom: Structures and Cytotoxicity
Leidos and Biosortia Pharmaceuticals Execute Memorandum of Understanding
MOU to explore a new business relationship focused on leveraging assets and drug discovery capabilities for immuno-oncology application
Guy T. Carter